Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Guozhong Venture Capital

BioCentury | Nov 3, 2022
Deals

Nov. 2 Quick Takes: CSL paying $200M for Arcturus’ mRNA vaccine tech

Plus Rubius seeking alternatives and updates from Horizon, Lilly-Innovent, GSK, Compass, Regeneron, Exelixis, CFIUS and more
BioCentury | Oct 12, 2021
Product Development

Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition

Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
Items per page:
1 - 5 of 5